Status:
RECRUITING
Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell Phenotype in Relation to Patient Age.
Lead Sponsor:
University of Jena
Collaborating Sponsors:
University Hospital Erlangen
Labor Prof. Pachmann
Conditions:
Tumor Cell, Circulating
Eligibility:
FEMALE
18+ years
Brief Summary
In a prospective study, the influence of adjuvant radiotherapy in patients with non-metastatic breast carcinoma on the epithelial tumor cells (CETCs) circulating in the blood and their immunohistochem...
Detailed Description
The primary aim of this prospective-explorative phase 0 study is to investigate the influence of adjuvant radiotherapy in patients with non-metastatic breast cancer on the circulating epithelial tumor...
Eligibility Criteria
Inclusion
- Primary diagnosis histologically confirmed invasive breast carcinoma pT1-4 pN0 or pN+ cM0
- curative-intended breast-conserving therapy (BET) ± (neo-) adj. system therapy with subsequent adjuvant radiotherapy of the breast ± lymphatic drainage system planned
- informed consent of the patient
Exclusion
- DCIS, Inflammatory breast carcinoma
- Recurrence situation
- Presence of distant metastases
- Second malignancies \< 10 years prior to diagnosis of breast carcinoma
- Prior exposure to radiotherapy
Key Trial Info
Start Date :
July 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04902937
Start Date
July 1 2021
End Date
December 31 2026
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiooncology, Jena
Jena, Germany, 07743